# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024S...
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issua...
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All Na...
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expect...
Biora Therapeutics, Inc.